Highlights
- Market Cap
- $517.68M
- Enterprise Value
- $579.21M
- EPS (TTM)
- -$1.38
- Total Revenue (TTM)
- $4.63M
- EBITDA (TTM)
- -$195.76M
- Year Range
- $1.11 - $6.94
- Target Price
- $17.25
- ROA (TTM)
- -58.69%
- ROE (TTM)
- -166.41%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Prime Medicine Inc. Common Stock, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Prime Medicine Inc. Common Stock (PRME) has returned 0.29% so far this year and 74.87% over the past 12 months.
Prime Medicine Inc. Common Stock
- 1D
- 10.48%
- 1M
- -24.68%
- YTD
- 0.29%
- 6M
- -37.18%
- 1Y
- 74.87%
- 3Y*
- -34.35%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Oct 20, 2022, PRME's average daily return is -0.01%, while the average monthly return is -0.25%.
Historically, 38% of months were positive and 62% were negative. The best month was Jun 2025 with a return of +109.3%, while the worst month was Oct 2023 at -32.0%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 7 months.
On a daily basis, PRME closed higher 45% of trading days. The best single day was May 16, 2025 with a return of +26.2%, while the worst single day was May 19, 2025 at -16.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 9.80% | 21.26% | -24.68% | 0.29% | |||||||||
| 2025 | -4.11% | -10.00% | -21.03% | -13.07% | -31.79% | 109.32% | 51.42% | -13.37% | 70.99% | -10.83% | -22.67% | -9.16% | 18.84% |
| 2024 | -28.33% | 35.91% | -18.89% | -29.71% | 31.71% | -20.68% | 9.14% | -23.71% | -9.58% | 0.26% | -15.21% | -11.25% | -67.04% |
| 2023 | -5.38% | -6.54% | -25.14% | 11.95% | -0.36% | 6.78% | 2.87% | -12.14% | -27.95% | -31.97% | 11.86% | 22.04% | -52.31% |
| 2022 | 22.45% | -8.66% | 8.09% | 20.88% |
Benchmark Metrics
Prime Medicine Inc. Common Stock has an annualized alpha of -31.97%, beta of 1.98, and R² of 0.12 versus S&P 500 Index. Calculated based on daily prices since October 21, 2022.
- This stock participated in 282.14% of S&P 500 Index downside but only 44.49% of its upside — more exposed to losses than it benefited from rallies.
- R² of 0.12 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -31.97%
- Beta
- 1.98
- R²
- 0.12
- Upside Capture
- 44.49%
- Downside Capture
- 282.14%
Return for Risk
Risk / Return Rank
PRME ranks 67 for risk / return — better than 67% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Prime Medicine Inc. Common Stock (PRME) and compare them to a chosen benchmark (S&P 500 Index).
| PRME | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.67 | 0.90 | -0.23 |
Sortino ratioReturn per unit of downside risk | 1.78 | 1.39 | +0.39 |
Omega ratioGain probability vs. loss probability | 1.19 | 1.21 | -0.02 |
Calmar ratioReturn relative to maximum drawdown | 1.42 | 1.40 | +0.02 |
Martin ratioReturn relative to average drawdown | 2.29 | 6.61 | -4.32 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore PRME risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Prime Medicine Inc. Common Stock. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Prime Medicine Inc. Common Stock was 94.55%, occurring on Apr 8, 2025. The portfolio has not yet recovered.
The current Prime Medicine Inc. Common Stock drawdown is 83.52%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -94.55% | Nov 2, 2022 | 609 | Apr 8, 2025 | — | — | — |
| -3.55% | Oct 24, 2022 | 1 | Oct 24, 2022 | 1 | Oct 25, 2022 | 2 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Prime Medicine Inc. Common Stock over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Prime Medicine Inc. Common Stock is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for PRME relative to other companies in the Biotechnology industry. Currently, PRME has a P/S ratio of 109.8. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for PRME in comparison with other companies in the Biotechnology industry. Currently, PRME has a P/B value of 4.3. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |